FormWeb • buprenorphine-naloxone

IHS FormWeb

Approved Formulary

Search by class Show Therapeutic Classes

Staff Telephone Numbers

Webpage Links

Add Formweb to your mobile device

Android iOS

IHS FormWeb

Approved Formulary

REMS FDA Documents (transmucosal)

Search results for:

buprenorphine-naloxone

buprenorphine-naloxone

Restricted Medications Non-Formulary
REMS FDA Documents (transmucosal)

Brand names: Bunavail, Suboxone, Zubsolv

No brands, forms, or strengths have been added for this generic.

Display Opioid Partial Agonists Class: 280812

Medication comments:

Per policy, use of these medications is restricted as noted below:
generic (Brand)	Restrictions
buprenorphine (Subutex, Suboxone)	New starts of buprenorphine for pain or dependence treatment will not be allowed at IHS. Indications for buprenorphine are limited to the following: (1) Continuation of buprenorphine therapy for the maintenance of opioid dependence when the patient is admitted for a medical condition other than opioid addiction. (2) Continuation of chronic pain management if buprenorphine was taken prior to admission. See policy for more details.

Per policy, use of these medications is restricted as noted below:

generic (Brand)

Restrictions

buprenorphine (Subutex, Suboxone)

New starts of buprenorphine for pain or dependence treatment will not be allowed at IHS. Indications for buprenorphine are limited to the following:
(1) Continuation of buprenorphine therapy for the maintenance of opioid dependence when the patient is admitted for a medical condition other than opioid addiction.
(2) Continuation of chronic pain management if buprenorphine was taken prior to admission.
See policy for more details.

Per policy, orders for these non-formulary agents will be changed to formulary equivalents.
Non-Formulary Agent	Formulary Equivalent
buprenorphine-naloxone (Suboxone, Zubsolv) tab	buprenorphine SL tablets - dose equivalent
buprenorphine-naloxone (Suboxone, Bunavail) sublingual film	buprenorphine SL tablets - dose equivalent

Last updated: Jun. 11, 2025

Therapeutic Interchange Policy buprenorphine (Subutex)
Black Box Warnings Addiction, Abuse, And Misuse; Respiratory Depression; Neonatal Opioid Withdrawal Syndrome; Risks From Concomitant Use With Benzodiazepines

UpToDate Lexidrug

Pharmacy Contact Info:

Main Inpatient Pharmacy: ext 4599, 3503
Fax: 704-878-7283

Director of Pharmacy - Randi Raynor, PharmD: ext 4501
Clinical Coordinator - Laura Rollings, PharmD: ext 4597
Pharmacy Informaticist - Stephen Pringle, PharmD: ext 7645
Pharmacy Technician Supervisor - Amy Wingler, CPhT: ext 7385
Pharmacy Automation Coordinator (Omnicell) - Melissa Fulford, CPhT: ext 3556

This site is intended for the staff of Iredell Health System. While others may view accessible pages, Iredell Health System makes no warranty, express or implied, as to the use of this information outside of Iredell Health System. The content of this policy and procedure document serves as guidance to the delivery of quality patient care. Care providers are expected to exercise critical thinking and situational awareness skills, and in specific situations to take such action as is necessary for the delivery of quality patient care.